The RIQAS CYFRA 21-1 EQA programme is designed to cover the analysis of CYFRA 21-1 in clinical laboratories when monitoring the response to treatment of cancers such as non-small cell lung carcinoma, cervical, breast and bladder cancer.
Lyophilised samples
Monthly reporting
Testing covers the full range of clinically relevant decision levels
Submit results and view reports online via RIQAS.net
12 month subscription
Not accredited to ISO/IEC 17043
Parameter
CYFRA 21-1 (Cytokeratin 19)